Differential Effect of Polymorphisms of CMPK1 and RRM1 on Survival in Advanced Non-small Cell Lung Cancer Patients Treated with Gemcitabine or Taxane/Cisplatinum-Reference-Cited by-同舟云学术

Differential Effect of Polymorphisms of CMPK1 and RRM1 on Survival in Advanced Non-small Cell Lung Cancer Patients Treated with Gemcitabine or Taxane/Cisplatinum

Published:2011-08 Issue:8 Volume:6 Page:1320-1329
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ryu Jeong-Seon,Shin Eun-Soon,Nam Hae-Seong,Yi Hyeon-Gyu,Cho Jae-Hwa,Kim Chul-Soo,Kim Hyun-Jung,Lee Jong-Eun

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Nationwide cancer incidence in Korea, 2003–2005;Won;Cancer Res Treat,2009

3. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

5. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975;Smit;J Clin Oncol,2003

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Transcriptomics and Proteomics Identified CMPK1 as a Potential Biomarker for Type 2 Diabetes Mellitus;Diabetes, Metabolic Syndrome and Obesity;2024-08

2. Mechanistic Modeling of Gene Regulation and Metabolism Identifies Potential Targets for Hepatocellular Carcinoma;Frontiers in Genetics;2020-12-23

3. Oncogenic KSHV-encoded interferon regulatory factor upregulates HMGB2 and CMPK1 expression to promote cell invasion by disrupting a complex lncRNA-OIP5-AS1/miR-218-5p network;PLOS Pathogens;2019-01-30

4. Molecular Markers for Treatment Response and Toxicity of Gemcitabine;Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy;2019

5. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism;Cancers;2018-07-23